Unichem Laboratories (NSE:UNICHEMLAB) Cyclically Adjusted Revenue per Share: ₹235.87 (As of Mar. 2026)


NSE:UNICHEMLAB Unichem Laboratories Ltd NSE:UNICHEMLAB
65 GF Score
Price ₹638.75
GF Value ₹691.31
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Unichem Laboratories Cyclically Adjusted Revenue per Share?

Unichem Laboratories NSE:UNICHEMLAB -1.82% 65 Cyclically Adjusted Revenue per Share is ₹235.87 as of Mar. 2026. GuruFocus rates NSE:UNICHEMLAB with a GF Score™ of 65/100 and a GF Value™ of ₹691.31 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Unichem Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was ₹81.708. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹235.87 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Unichem Laboratories's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-10), Unichem Laboratories's current stock price is ₹638.75. Unichem Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹235.87. Unichem Laboratories's Cyclically Adjusted PS Ratio of today is 2.71.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Unichem Laboratories was 4.30. The lowest was 1.22. And the median was 2.27.


Unichem Laboratories  (NSE:UNICHEMLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Unichem Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=638.75/235.87
=2.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Unichem Laboratories was 4.30. The lowest was 1.22. And the median was 2.27.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Unichem Laboratories Cyclically Adjusted Revenue per Share Related Terms


Unichem Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Unichem Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unichem Laboratories Cyclically Adjusted Revenue per Share Chart

Unichem Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 217.47 235.87

Unichem Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 217.47 221.58 228.20 232.22 235.87

NSE:UNICHEMLAB vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Unichem Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unichem Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unichem Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Unichem Laboratories's Cyclically Adjusted PS Ratio falls into.


NSE:UNICHEMLAB
65GF Score
Unichem Laboratories Ltd NSE:UNICHEMLAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unichem Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Unichem Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=81.708/164.2724*164.2724
=81.708

Current CPI (Mar. 2026) = 164.2724.

Unichem Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201203 0.000 76.889 0.000
201303 0.000 85.687 0.000
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 17.787 105.196 27.776
201712 0.000 109.404 0.000
201803 21.930 109.786 32.814
201806 34.306 111.317 50.626
201809 37.105 115.142 52.938
201812 40.069 115.142 57.166
201903 45.184 118.202 62.795
201906 38.851 120.880 52.797
201909 38.032 123.175 50.721
201912 38.973 126.235 50.716
202003 33.486 124.705 44.111
202006 45.608 127.000 58.993
202009 45.097 130.118 56.934
202012 46.393 130.889 58.226
202103 32.577 131.771 40.612
202106 42.267 134.084 51.783
202109 41.274 135.847 49.910
202112 44.363 138.161 52.747
202203 48.843 138.822 57.798
202206 43.986 142.347 50.761
202209 46.717 144.661 53.050
202212 42.966 145.763 48.422
202303 51.294 146.865 57.374
202306 56.990 150.280 62.296
202309 59.060 151.492 64.043
202312 66.086 152.924 70.990
202403 58.668 153.035 62.976
202406 67.715 155.789 71.402
202409 71.892 157.882 74.802
202412 75.471 158.323 78.307
202503 83.138 157.552 86.684
202506 74.942 159.755 77.061
202509 82.291 162.289 83.297
202512 73.889 163.281 74.338
202603 81.708 164.272 81.708

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹235.87 mean?
Unichem Laboratories (NSE:UNICHEMLAB) has a Cyclically Adjusted Revenue per Share of ₹235.87 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Unichem Laboratories and its competitors.
Is Unichem Laboratories' Cyclically Adjusted Revenue per Share too high?
Unichem Laboratories' current Cyclically Adjusted Revenue per Share is ₹235.87. Overall, Unichem Laboratories has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unichem Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Unichem Laboratories' Cyclically Adjusted Revenue per Share of ₹235.87 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Unichem Laboratories and its competitors. Unichem Laboratories's current Cyclically Adjusted Revenue per Share is ₹235.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unichem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Unichem Laboratories (NSE:UNICHEMLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹691.31, compared to a current price of ₹638.75 — trading 7.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹235.87. Unichem Laboratories' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Unichem Laboratories (NSE:UNICHEMLAB), the current Cyclically Adjusted Revenue per Share is ₹235.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Unichem Laboratories (NSE:UNICHEMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Unichem Laboratories stock appears to be undervalued. The current stock price of ₹638.75 is trading 7.6% below its estimated GF Value™ of ₹691.31. GuruFocus considers Unichem Laboratories to be Fairly Valued.

Key valuation signals for NSE:UNICHEMLAB:

  • Cyclically Adjusted Revenue per Share: ₹235.87
  • GF Value™: ₹691.31 vs. price of ₹638.75 (7.6% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the NSE:UNICHEMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Unichem Laboratories Business Description

Other Exchanges 506690:India
Address Off. S. V. Road, Unichem Bhavan, Prabhat Estate, Jogeshwari (West), Mumbai, MH, IND, 400 102
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
65GF Score

Get the complete analysis for NSE:UNICHEMLAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹638.75
Price
₹691.31
GF Value